. During this period, there were 338 pediatric deaths from influenza, of which 83% (282 cases) were confirmed H1N1. This mortality was higher than the 153 pediatric deaths from seasonal influenza during 2003-2004 (2) .
An adult study reported that those with pandemic H1N1 had higher rates of extrapulmonary complications, intensive care unit (ICU) admissions, and/or death compared to those with seasonal influenza (3) . In this study, bacterial superinfection was associated with an increased risk of ICU admission and/or death. Pediatric studies reported that 7% of the pediatric deaths from 2003 to 2004 seasonal influenza had coinfections with Staphylococcus aureus (2) . Bacterial superinfection also occurred frequently (23%) in pediatric patients with H1N1 (4). Our parent study reported that children with 2009 pandemic H1N1 and methicillin-resistant S. aureus (MRSA) pulmonary coinfection had a higher risk of death than those without MRSA. In addition, thrombocytopenia at admission was associated with an increased risk of death (5) .
Despite published data regarding the epidemiology of H1N1 infection (1, 2) , there are limited data on the mechanisms of increased mortality (2) . Data from our parent study suggest a role of both secondary bacterial infections and coagulopathy in H1N1-associated mortality (5) . Disseminated intravascular coagulation (DIC) occurs in 50% of pediatric patients with severe sepsis and is associated with high morbidity and mortality (6) (7) (8) (9) . The purpose of this study was to evaluate the Objectives: H1N1 influenza with coinfections has been implicated to have high morbidity and mortality. We hypothesized that critically ill children with 2009 H1N1 and coinfections are at a higher risk of developing disseminated intravascular coagulation.
Design: The chart review included demographics, Data Collection. Following the parent study closure, we extracted our site's data from the multicenter database and, under a separate institutional review board protocol, supplemented these with coagulation parameters not collected in the parent data set. We thought that collecting data on days 1, 3, and 7 would give us a good clinical picture of whether or not the infections would trigger a severe coagulopathy as others have reported that 75% of critically ill children progressed to the highest DIC score within 6 hrs of PICU admission (9) .
Baseline demographic information, duration of illness, presenting symptoms, initial PICU admission findings, selected clinical events, and outcomes were recorded in a REDCap (10) web-based electronic case report form. Data were collected on pathogens identified from blood and respiratory secretions throughout the PICU hospitalization. Mortality was defined as death occurring anytime during the PICU stay and up to hospital day 90 for patients transferred to the ward.
Inclusion/Exclusion Criteria. Inclusion criteria were as follows: 1) confirmed (defined as a person with an acute illness admitted to an ICU with laboratory-confirmed influenza A or B virus infection) or suspected influenza infection (defined as a person admitted to the ICU without a positive influenza test but where the clinical team's suspicion for influenza was enough to treat empirically with antivirals for influenza for the lesser of 5 days or until death). If another diagnosis was found to explain the patient's acute illness (e.g., respiratory syncytial virus), then the person was not considered a suspected case for this registry); 2) only patients with community-acquired infections, documented by positive viral or bacterial cultures sampled ≤72 hrs of admission from a sterile site (respiratory secretions or blood) were eligible for inclusion in the study; and 3) admission to an ICU at a participating site. Exclusion criteria were influenzalike illness due to noninfluenza disease and negative testing for influenza.
Definitions. Patients were categorized as previously healthy if they were healthy prior to the index illness, without underlying medical conditions and not dependent on any medications or medical devices. Pediatric Risk of Mortality III acute physiology score (PRISM III) (11) was used to measure severity of illness within the first 24 hrs of admission.
Shock requiring inotropes/vasopressors was defined as dopamine infusion >5 µg/kg/ min or any epinephrine, or norepinephrine infusion to maintain adequate blood pressure (12) .
A clinically relevant bacterial coinfection was defined as 1) a clinical diagnosis of bacterial pneumonia for which antibiotics were started, 2) evidence of bacterial superinfection within 72 hrs of the initial PICU admission from a sterile site (respiratory secretions or blood), and 3) a bacterial pathogen identified in their respiratory secretions.
A confirmed case of 2009 H1N1 was defined as a respiratory specimen that tested positive for 2009 H1N1 virus infection by real-time polymerase chain reaction testing using primers specific for 2009 H1N1 virus or viral culture. A patient with influenza A was defined as a PICU patient with a respiratory specimen that tested positive for influenza A virus infection by any influenza testing without further identification of subtype. These patients were possibly also H1N1, because early testing by PCR was found to be inaccurate as the primers used were not specific for H1N1.
Regular dose oseltamivir was defined by the 2009 Centers for Disease Control and Prevention recommendations (13), as follows: <12 months: 3 mg/kg/dose twice daily; ≤15 kg: 30 mg twice daily; >15 kg to ≤23 kg: 45 mg twice daily; >23 kg to ≤40 kg: 60 mg twice daily; >40 kg: 75 mg twice daily. High dose oseltamivir was defined as twice the regular dose.
Disseminated Intravascular Coagulation. DIC was defined according to the Scientific Subcommittee on DIC of the International Society on Thrombosis and Haemostasis (14) . Coagulation tests were scored as follows: platelet count: >100,000/m 3 = 0; ≤100,000/mm 3 = 2; d-dimer: no increase (<0.4 µg/mL of fibrinogen equivalent unit) = 0, moderate increase (0.4-4.0 µg/mL fibrinogen equivalent unit) = 2; strong increase (≥4 µg/mL fibrinogen equivalent unit) = 3; prothrombin time: <18 secs = 0, >18 secs by <24 secs = 1, if >24 secs = 2; fibrinogen level: ≥1.0 g/L = 0, <1.0 g/L = 1. If the score was ≥5, it was considered overt DIC. If the score was <5, it was suggestive (not affirmative) for nonovert DIC. 
Statistics.
Patients were classified into three groups based on their initial coinfection results. Patients with methicillin-sensitive or -
RESULTS
We enrolled 66 patients (59% male; age 5.9 ± 5.4 yrs [mean ± sd]) ( Table 1) . Sixty-four percent of patients were PCRconfirmed H1N1 and 36% of patients were influenza A positive (not subtyped by PCR, rapid or culture). Fifty-one percent of the patients had bacterial coinfections. Eighteen percent, 33%, and 48% of the patients had MSSA/MRSA, other pathogens, and no coinfections, respectively. Fifty-five percent of patients had comorbidities.
The bacterial coinfections identified were S. aureus in 35%, Pseudomonas aeruginosa in 18%, Moraxella catarrhalis in 18%, Haemophilus influenza (nontypable) in 9%, Streptococcus pneumoniae in 6%, Group A streptococcus in 6%, and Serratia marcescens in 9% (Table 2) .
Fifty-nine percent and 20% of patients were treated with high and regular dose oseltamivir, respectively. Two patients did not receive any antivirals. The remaining patients were treated with amantadine, peramivir, ribavirin, and/or zanamivir. Of the patients with MSSA/MRSA, one patient received regular dose oseltamivir, six received high dose oseltamivir, and five received other antivirals. None of the patients with MSSA/MRSA coinfections received steroids at admission, whereas 19% of patients without coinfections received steroids.
PRISM III scores were significantly higher in patients with MSSA/MRSA than in patients with no coinfections (p < .05; Mann-Whitney) ( Table 3) . Although patients with MSSA/MRSA had longer length-of-stay than patients with other and no coinfections, this did not reach statistical significance. The need for extracorporal membrane oxygenation or inotropes/vasopressors or survival was not significantly different between groups. Three patients (two with MSSA/ MRSA and one with no coinfections) were on extracorporal membrane oxygenation. Survival at day 90 was 83.3%, 95.5%, and 90.6% in patients with MSSA/MRSA, other, and no coinfections, respectively (p = .51).
International normalized ratio, d-dimer, and prothrombin time were significantly higher on days 1 and 3 in patients with MSSA/MRSA than in patients with other coinfections, respectively (p < .05; Mann-Whitney) ( Table 4) . There was no significant difference for platelet counts between the three groups.
DIC scores on days 1, 3, and 7 are calculated in Table 4 . DIC scores on days 1 and 3 were significantly higher in MSSA/ MRSA coinfections compared to other coinfections, respectively (p < .05; MannWhitney). DIC scores on day 7 were significantly higher in MSSA/MRSA coinfections compared to no coinfections (p < .05).
Patients with MSSA/MRSA had a significantly higher risk of having a PRISM III score ≥10 and of having DIC compared to patients with no coinfections (Table 5) .
Interestingly, patients with other coinfections were not significantly more likely to have higher PRISM III score nor have DIC compared to patients with no coinfections.
DISCUSSION
In our observational study, we demonstrate that MSSA/MRSA coinfection is associated with a higher risk of developing DIC in pediatric patients with H1N1, which may partially explain the increased mortality seen worldwide from pandemic H1N1.
Since the inception of the Centers for Disease Control and Prevention surveillance for laboratory-confirmed influenzarelated deaths among children in 2004 (2), the reports of pediatric hospitalization and death were the highest during the 2009-2010 pandemic H1N1 influenza season (15) . Bacterial coinfections with influenza have been increasing over the past years from 6% in 2004-2005 to 34% in 2006-2007 (16) . These coinfections had been associated with higher morbidity and mortality (17) . In our study, we report that 51% of critically ill children with H1N1 have bacterial coinfections, of which 35% were S. aureus. The overall mortality was 9% for our study, but the mortality associated with S. aureus was 33%. This is higher than the 2004-2007 Centers for Disease Control and Prevention report, wherein 13% of the pediatric influenza deaths were associated with S. aureus coinfections (16) .
S. aureus has been previously associated with severe pneumonia in the 1918 influenza pandemic (18) , with an increased incidence of pneumonia (19) and toxic shock syndrome in the 1968-1969 Hong Kong flu epidemic (20) and increased mortality (21) . We found that children with H1N1 influenza and S. aureus coinfections presented sicker to our ICU as evidenced by having a higher PRISM III score and a higher risk of having DIC. Two of the three children who required extracorporal membrane oxygenation for hypoxic respiratory failure and catecholamine-refractory shock were coinfected with S. aureus. A number of mechanisms have been proposed as to why influenza A infection may make the host more susceptible to bacterial superinfection. Previous murine models of influenza A suggested that epithelial damage and changes in surface receptor caused by the virus put the host at risk for bacterial superinfection (22, 23) . In a recent H1N1 influenza murine model, investigators found that mice with prior influenza infection were significantly susceptible to secondary S. aureus superinfection due to impaired natural killer cell responses in the lung (24) .
We found that children with S. aureus coinfections were four times more likely to develop overt DIC based on the International Society on Thrombosis and Haemostasis criteria (14) . Autopsy findings from DIC patients revealed extensive fibrin deposition in small and mid-size vessels in all organs (25) . Neutrophil extracellular traps (NETs) are webs of DNA fibers which contain histones and neutrophil antimicrobial proteins (26) and are proposed to be an innate response to trap and kill invasive bacteria (27) . Histones from NETs have been shown to activate platelets, promote thrombin formation and fibrin deposition, cause microvascular thrombosis, and become a major mediator of death in sepsis (28) (29) (30) (31) . S. aureus can rapidly induce neutrophils to release their DNA to form NETs via the release of Panton-Valentine leukocidin, a poreforming toxin. Furthermore, S. aureus is a more potent and rapid inducer of NETs release compared to other bacteria (26) . Thus, NETs could be the link between S. aureus infection and DIC. Study Limitations. We retrospectively reviewed the association between influenza A and bacterial coinfections in 66 patients admitted at a single center. As with all association studies, cause and effect cannot be determined from our data. Only 64% of our patients were PCRconfirmed H1N1. The other 36% of influenza A patients came early in the season during which testing by PCR was found to be inaccurate as the primers used were not specific for H1N1. However, later in the season all of our influenza A patients were PCR-confirmed H1N1.
CONCLUSIONS
During the 2009-2010 H1N1 pandemic, pediatric patients with influenza A and MSSA/MRSA coinfections had a higher risk of developing DIC. This higher risk for DIC may partially explain the increased mortality seen worldwide from pandemic H1N1. Further studies are warrant to evaluate the association between with influenza A and DIC.
